Table 1.
Outcome of 30 Studies That Reported Individual Patient Data Regarding the Use of Rifampicin or Not
| Category | N Studies | N Patients | Cure With Rifampicinb | Cure Without Rifampicinb | RR (95% CI) |
|---|---|---|---|---|---|
| Hip PJIa | |||||
| Staphylococcus aureus | 0 | ||||
| CNS | 0 | ||||
| Combined | 4 | 157 | 102/123 (83%) | 28/34 (82%) | 1.01 (0.85–1.20) |
| Knee PJIa | |||||
| S aureus | 1 | 22 | 9/22 (41%) | ||
| CNS | 0 | ||||
| Combined | 2 | 108 | 56/69 (81%) | 17/34 (50%) | 1.62 (1.14–2.31) |
| Hip and knee PJIc | |||||
| S aureus | 3 | 135 | 100/125(80%) | 4/10 (40%) | 2.00 (0.93–4.29) |
| CNS | 0 | ||||
| Combined | 24 | 1652 | 903/1298 (70%) | 186/354 (53%) | 1.32 (1.19–1.47) |
Abbreviations: CI, confidence interval; CNS, coagulase-negative staphylococci; PJI, prosthetic joint infection; RR, risk ratio.
aPooled individual patient data in N studies.
bPer-category studies are included if outcome is reported apart for S aureus and/or CNS apart or combined if outcome for all staphylococci is summarized.
cStudies are included in this category if outcome was reported only for hip and knee PJI together.